Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5B | Q9UGL1 | 15/20 | 0.48 |
| ▸ | KDM5C | P41229 | 10/20 | 0.48 |
| ▸ | KDM5A | P29375 | 7/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.48 |
| ▸ | KDM4A | O75164 | 4/20 | 0.43 |
| ▸ | KDM4B | O94953 | 2/20 | 0.43 |
| ▸ | KDM6B | O15054 | 2/20 | 0.43 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.43 |
| ▸ | KDM5D | Q9BY66 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.38 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.38 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27426145 | 0.84 | ACACB (0.43) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL27425092 | 0.83 | KDM5B (0.42) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL15637121 | 0.80 | KDM5B (0.62) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL27426210 | 0.80 | SLC7A5 (0.43) | KDM5BKDM5CKDM5AKDM4CKDM6B | |
| SCHEMBL22005801 | 0.78 | KDM5C (0.55) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL28040010 | 0.78 | SLC7A5 (0.44) | KDM5BKDM5CKDM5AKDM4CKDM6B | |
| SCHEMBL12682404 | 0.77 | ATR (0.47) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL31133034 | 0.77 | ATR (0.47) | KDM5BKDM5CKDM5AKDM4CKDM4A | |
| SCHEMBL509487 | 0.77 | KDM5B (0.53) | KDM5BKDM5CKDM5AKDM4CKDM4E | |
| SCHEMBL27427192 | 0.77 | SLC7A5 (0.40) | KDM5BKDM5CKDM5AKDM4CKDM6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314217-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20110224130-A1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | THERAVANCE, INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-7067481-B2 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE, INC. (US) | 2006-06-27 | — | — | US | disclosed |
| US-20040266666-A1 | Cross-linked glycopeptide-cephalosporin antibiotics | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266666-A1 | Cross-linked glycopeptide-cephalosporin antibiotics | GYPA, CSGALNACT1, ST3GAL3 | KDM5B 3012/4885KDM5C 3134/4885KDM5A 3605/4885 |
| US-20110224130-A1 | CROSS-LINKED GLYCOPEPTIDE-CEPHALOSPORIN ANTIBIOTICS | CSGALNACT1, GYPA, ST3GAL3 | KDM5B 3008/4885KDM5C 3289/4885KDM5A 3488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.